Tariffs should spare vital US medtech industry
In this must-read op-ed originally published in The Baltimore Sun, AdvaMed President and CEO Scott Whitaker lays out a compelling argument for protecting the U.S. medical technology industry from the unintended consequences of broad-based tariffs. With more than 95% of medtech R&D taking place in the U.S. and over 3 million American jobs at stake, Whitaker emphasizes the critical role the industry plays in both the economy and public health.
He urges policymakers to adopt a reciprocal “zero-for-zero” tariff policy on life-saving and life-enhancing medtech products, protecting innovation and ensuring access for patients. This op-ed provides valuable context for understanding AdvaMed’s advocacy efforts and the high stakes involved in the current trade debate.